A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

a study on Eosinophilic Esophagitis

Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at Oakland 5378538, California 5332921 and other locations
Dates
study started
study ends around

Description

Summary

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.

Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.

Patient questionnaires will measure the following:

  • How EoE makes one feel
  • EoE symptoms
  • How EoE affects quality-of-life
  • How EoE impacts aspects of daily life
  • How difficult it is to swallow
  • How EoE symptoms have changed throughout the study

Official Title

A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care

Keywords

Eosinophilic Esophagitis (EoE), Eosinophilic Esophagitis, dupilumab

Eligibility

You can join if…

Open to people ages 12 years and up

  1. Initiating treatment with DUPIXENT® for EoE according to the USPI
  2. Able to understand and complete registry-related questionnaires (including adolescents)

You CAN'T join if...

  1. Patients who have a contraindication to DUPIXENT® according to the USPI
  2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
  3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)

NOTE: Other protocol defined inclusion/exclusion criteria apply

Locations

  • UCSF accepting new patients
    Oakland 5378538 California 5332921 94609 United States
  • University of Southern California Keck School of Medicine accepting new patients
    Los Angeles 5368361 California 5332921 90033 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Regeneron Pharmaceuticals
ID
NCT06693531
Study Type
Observational [Patient Registry]
Participants
Expecting 300 study participants
Last Updated
Contact us about this trial